Anteris Technologies Global Corp
Research Anteris Technologies Global Corp (AVR) on Bullrun: market cap USD 659.47M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAVR
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 659.47M
- Financial periodQ2 2026
- RevenueUSD 1.01M
- Net income-USD 29.09M
- Free cash flow-USD 21.45M
- Gross margin76.9%
Valuation Snapshot
latest market cap is USD 659.47M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.91M | -USD 94.14M | -USD 79.76M | 70.3% | -2.55 | USD 12.58M | USD 2.28M | -USD 93.00K |
| FY2024 | USD 2.70M | -USD 76.29M | -USD 63.51M | 46.8% | -3.68 | USD 70.46M | USD 1.40M | USD 62.76M |
| FY2023 | USD 2.80M | -USD 45.87M | -USD 37.47M | 61.2% | -2.94 | USD 21.01M | USD 1.71M | USD 19.49M |
| FY2022 | USD 3.12M | -USD 30.16M | -USD 28.17M | 56.8% | -2.26 | USD 9.39M | USD 956.72K | USD 8.99M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 659.47M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 207.48M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 200.54M | n/a | n/a | n/a |
About Anteris Technologies Global Corp
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Anteris Technologies Global Corp's market cap?
Anteris Technologies Global Corp's market capitalization is USD 659.47M.
What does Anteris Technologies Global Corp do?
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.